Balaji Amines

Balaji Amines reported a strong sequential improvement in Q4 FY25. Consolidated revenue from operations increased to INR361 crores, up 12.5% from INR321 crores in Q3 FY25. EBITDA grew by 25.9% QoQ to INR68 crores, with the EBITDA margin expanding to 19% from 17%. Consolidated PAT also saw a significant QoQ increase of 29.0% to INR40 crores. Total volumes for the quarter reached 25,871 metric tons, a 7.3% QoQ increase, driven by stable demand from the pharmaceutical sector.

For the full financial year 2025, consolidated revenue from operations stood at INR1,430 crores, a 14.5% decline from INR1,671 crores in FY24. Consolidated EBITDA was INR267 crores (corrected from INR265 crores), down 24.4% YoY, resulting in a 19% EBITDA margin compared to 21% in FY24. PAT for FY25 decreased by 31.5% YoY to INR159 crores. Management attributed the full-year challenges to input cost pressures, pricing volatility, and global uncertainties.

The company is actively expanding its capacities and product portfolio. The 8-megawatt DC solar power plant was commissioned in April 2025, contributing to cost reduction and ESG goals. The Propylene Glycol pharma grade plant is expected to be commissioned in Q1 FY26. The Dimethyl Ether (DME) and N-Methyl Morpholine (NMM) plants are planned for commissioning by the end of FY26. Additionally, an acetonitrile plant expansion to 60 metric tons per day is expected by FY27, and a new NBPT plant is slated for commencement in the next financial year.

Balaji Specialty Chemicals Limited (BSC), the subsidiary, is executing a greenfield project worth approximately INR750 crores. Phase 1, focusing on Hydrogen Cyanide, Sodium Cyanide, and EDTA derivatives, is valued at INR350-400 crores and is expected to be commissioned by the end of FY26. Phase 2, also INR350-400 crores, will follow after FY27. A brownfield expansion for EDA-based products at Unit I is also on track for commissioning in FY26-27, aiming to enhance the product portfolio.

The DME plant, with a total capacity of 100,000 tons, is ready for commissioning, pending PESO regulatory approvals. Management anticipates 50-60% capacity utilization in the current year, potentially increasing to 70% next year, with an estimated revenue of INR70-75 per kg. DME is positioned as an alternative for LPG, with BIS allowing 20% blending, and also targets the aerosol market and industrial heating applications, offering significant market potential upon regulatory clearance.

The company faces challenges from external factors, including volatile agrochemical demand and rising raw material prices. Methanol prices increased by INR7-8 per kg recently due to geopolitical tensions between Iran and Israel, creating uncertainty for profitability. China's dumping practices continue to impact the EDA segment, leading to current utilization of 40-50% and ongoing anti-dumping investigations, which have also affected the subsidiary's overall performance.

Current N-Butylamine capacity utilization stands at 30-35%, with management expecting it to exceed 80% next financial year, aiming to capture 90-95% of India's import demand. The company is also upgrading its Dimethyl Carbonate (DMC) plants for Electronic DMC, commissioned in May 2025. Furthermore, Balaji Amines is pursuing a pharmaceutical grade license for Propylene Glycol, which would enable the plant to operate at over 60-70% capacity even without full demand from battery chemicals, diversifying revenue streams.